Global Metabolic Disorders Therapeutics Market Size, Status and Forecast 2020-2026

Published On: Aug 2020

Format: PDF

Publisher: QY Research

Pages: 91

Report ID: 228420

Metabolic Disorders Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Metabolic Disorders Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AbbVie
Novo Nordisk
Actelion Pharmaceuticals
Sanofi
Biocon
Merck
Boehringer Ingelheim
AstraZeneca
CymaBay Therapeutics
Eli Lilly and Company

Market segment by Type, the product can be split into
Metachromatic Leukodystrophy
Globoid Leukodystrophy
Hepatic Encephalopathy
Others
Market segment by Application, split into
Diabetes
Obesity
Hypercholesterolemia
Lysosomal Storage Diseases
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Metabolic Disorders Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Metachromatic Leukodystrophy
1.4.3 Globoid Leukodystrophy
1.4.4 Hepatic Encephalopathy
1.4.5 Others
1.5 Market by Application
1.5.1 Global Metabolic Disorders Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Diabetes
1.5.3 Obesity
1.5.4 Hypercholesterolemia
1.5.5 Lysosomal Storage Diseases
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Metabolic Disorders Therapeutics Market Perspective (2015-2026)
2.2 Global Metabolic Disorders Therapeutics Growth Trends by Regions
2.2.1 Metabolic Disorders Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Metabolic Disorders Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Metabolic Disorders Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Metabolic Disorders Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Metabolic Disorders Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorders Therapeutics Players by Market Size
3.1.1 Global Top Metabolic Disorders Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Metabolic Disorders Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Metabolic Disorders Therapeutics Market Concentration Ratio
3.2.1 Global Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Metabolic Disorders Therapeutics Revenue in 2019
3.3 Metabolic Disorders Therapeutics Key Players Head office and Area Served
3.4 Key Players Metabolic Disorders Therapeutics Product Solution and Service
3.5 Date of Enter into Metabolic Disorders Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Metabolic Disorders Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Metabolic Disorders Therapeutics Market Size by Application (2015-2020)
5.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Metabolic Disorders Therapeutics Market Size (2015-2020)
6.2 Metabolic Disorders Therapeutics Key Players in North America (2019-2020)
6.3 North America Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
6.4 North America Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Metabolic Disorders Therapeutics Market Size (2015-2020)
7.2 Metabolic Disorders Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
7.4 Europe Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Metabolic Disorders Therapeutics Market Size (2015-2020)
8.2 Metabolic Disorders Therapeutics Key Players in China (2019-2020)
8.3 China Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
8.4 China Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Metabolic Disorders Therapeutics Market Size (2015-2020)
9.2 Metabolic Disorders Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
9.4 Japan Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Metabolic Disorders Therapeutics Market Size (2015-2020)
10.2 Metabolic Disorders Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Metabolic Disorders Therapeutics Market Size (2015-2020)
11.2 Metabolic Disorders Therapeutics Key Players in India (2019-2020)
11.3 India Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
11.4 India Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Metabolic Disorders Therapeutics Market Size (2015-2020)
12.2 Metabolic Disorders Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Metabolic Disorders Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Metabolic Disorders Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AbbVie
13.1.1 AbbVie Company Details
13.1.2 AbbVie Business Overview
13.1.3 AbbVie Metabolic Disorders Therapeutics Introduction
13.1.4 AbbVie Revenue in Metabolic Disorders Therapeutics Business (2015-2020))
13.1.5 AbbVie Recent Development
13.2 Novo Nordisk
13.2.1 Novo Nordisk Company Details
13.2.2 Novo Nordisk Business Overview
13.2.3 Novo Nordisk Metabolic Disorders Therapeutics Introduction
13.2.4 Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.2.5 Novo Nordisk Recent Development
13.3 Actelion Pharmaceuticals
13.3.1 Actelion Pharmaceuticals Company Details
13.3.2 Actelion Pharmaceuticals Business Overview
13.3.3 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Introduction
13.3.4 Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.3.5 Actelion Pharmaceuticals Recent Development
13.4 Sanofi
13.4.1 Sanofi Company Details
13.4.2 Sanofi Business Overview
13.4.3 Sanofi Metabolic Disorders Therapeutics Introduction
13.4.4 Sanofi Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.4.5 Sanofi Recent Development
13.5 Biocon
13.5.1 Biocon Company Details
13.5.2 Biocon Business Overview
13.5.3 Biocon Metabolic Disorders Therapeutics Introduction
13.5.4 Biocon Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.5.5 Biocon Recent Development
13.6 Merck
13.6.1 Merck Company Details
13.6.2 Merck Business Overview
13.6.3 Merck Metabolic Disorders Therapeutics Introduction
13.6.4 Merck Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.6.5 Merck Recent Development
13.7 Boehringer Ingelheim
13.7.1 Boehringer Ingelheim Company Details
13.7.2 Boehringer Ingelheim Business Overview
13.7.3 Boehringer Ingelheim Metabolic Disorders Therapeutics Introduction
13.7.4 Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.7.5 Boehringer Ingelheim Recent Development
13.8 AstraZeneca
13.8.1 AstraZeneca Company Details
13.8.2 AstraZeneca Business Overview
13.8.3 AstraZeneca Metabolic Disorders Therapeutics Introduction
13.8.4 AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.8.5 AstraZeneca Recent Development
13.9 CymaBay Therapeutics
13.9.1 CymaBay Therapeutics Company Details
13.9.2 CymaBay Therapeutics Business Overview
13.9.3 CymaBay Therapeutics Metabolic Disorders Therapeutics Introduction
13.9.4 CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.9.5 CymaBay Therapeutics Recent Development
13.10 Eli Lilly and Company
13.10.1 Eli Lilly and Company Company Details
13.10.2 Eli Lilly and Company Business Overview
13.10.3 Eli Lilly and Company Metabolic Disorders Therapeutics Introduction
13.10.4 Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2015-2020)
13.10.5 Eli Lilly and Company Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details